PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy
PMGC Holdings Inc. (NASDAQ: ELAB) has announced the sale of its skincare subsidiary, Elevai Skincare, as part of its strategic transformation. The divestiture will strengthen the company's balance sheet through approximately $1.1 million in Carmell stock and a 5% royalty on skincare revenues over the next five years, plus milestone payments.
The sale reduces operational losses and positions PMGC for new growth opportunities. The company maintains three subsidiaries: Elevai Biosciences, focusing on aesthetic medicines including EL-22 for muscle preservation during weight loss treatments; Elevai Research, utilizing Canadian research grants; and PMGC Capital , a multi-strategy investment vehicle.
The company aims to pursue transformative acquisitions and build a diversified portfolio focused on substantial growth and shareholder value creation.
PMGC Holdings Inc. (NASDAQ: ELAB) ha annunciato la vendita della sua controllata per la cura della pelle, Elevai Skincare, come parte della sua trasformazione strategica. La dismissione rafforzer脿 il bilancio dell'azienda attraverso circa 1,1 milioni di dollari in azioni Carmell e una royalty del 5% sui ricavi per la cura della pelle nei prossimi cinque anni, oltre a pagamenti legati a risultati specifici.
La vendita riduce le perdite operative e posiziona PMGC per nuove opportunit脿 di crescita. L'azienda mantiene tre controllate: Elevai Biosciences, focalizzata su medicine estetiche, incluso EL-22 per la preservazione muscolare durante i trattamenti di perdita di peso; Elevai Research, che sfrutta finanziamenti per la ricerca canadese; e PMGC Capital, un veicolo di investimento multi-strategia.
L'azienda mira a perseguire acquisizioni trasformative e a costruire un portafoglio diversificato focalizzato su una crescita sostanziale e sulla creazione di valore per gli azionisti.
PMGC Holdings Inc. (NASDAQ: ELAB) ha anunciado la venta de su subsidiaria de cuidado de la piel, Elevai Skincare, como parte de su transformaci贸n estrat茅gica. La desinversi贸n fortalecer谩 el balance de la empresa con aproximadamente 1,1 millones de d贸lares en acciones de Carmell y una regal铆a del 5% sobre los ingresos por cuidado de la piel durante los pr贸ximos cinco a帽os, adem谩s de pagos por hitos.
La venta reduce las p茅rdidas operativas y posiciona a PMGC para nuevas oportunidades de crecimiento. La compa帽铆a mantiene tres subsidiarias: Elevai Biosciences, enfocada en medicamentos est茅ticos, incluido EL-22 para la preservaci贸n muscular durante tratamientos de p茅rdida de peso; Elevai Research, que utiliza subvenciones de investigaci贸n canadienses; y PMGC Capital, un veh铆culo de inversi贸n de m煤ltiples estrategias.
La empresa tiene como objetivo seguir adquisiciones transformadoras y construir un portafolio diversificado centrado en un crecimiento sustancial y la creaci贸n de valor para los accionistas.
PMGC Holdings Inc. (NASDAQ: ELAB)電� 鞝勲灥鞝� 氤�頇橃潣 鞚柬櫂鞙茧 鞀ろ偍旒�鞏� 鞛愴殞靷皜 韽磩鞝侅澑 Elevai Skincare鞚� 毵り皝鞚� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 毵り皝鞚� 鞎� 110毵� 雼煬鞚� Carmell 欤检嫕瓿� 頄ロ泟 5雲� 霃欖晥 鞀ろ偍旒�鞏� 毵れ稖鞐� 雽�頃� 5% 搿滌棿韹�鞕� 鞚挫爼響� 歆�旮夓潉 韱淀暣 須岇偓鞚� 鞛 靸來儨毳� 臧曧檾頃� 瓴冹瀰雼堧嫟.
鞚措矆 毵り皝鞚� 鞖挫榿 靻愳嫟鞚� 欷勳澊瓿� PMGC臧� 靸堧鞖� 靹膘灔 旮绊殞毳� 氇儔頃橂姅 雿� 霃勳泙鞚� 霅╇媹雼�. 須岇偓電� 雼れ潓鞚� 靹� 臧滌潣 鞛愴殞靷ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟: Elevai Biosciences, 觳挫 臧愳唽 旃橂 欷� 攴检湣 氤挫〈鞚� 鞙勴暅 EL-22毳� 韽暔頃橂姅 氙胳毄 鞚橅暀鞐� 欷戩爯鞚� 霊愱碃 鞛堨溂氅�; Elevai Research, 旌愲倶雼� 鞐瓣惮 氤挫“旮堨潉 頇滌毄頃橂姅 須岇偓; 攴鸽Μ瓿� PMGC Capital, 雼り皝鞝� 韴瀽 鞛レ箻鞛呺媹雼�.
須岇偓電� 氤�順侅爜鞚� 鞚胳垬頃╇硲鞚� 於旉惮頃橁碃 靸侂嫻頃� 靹膘灔瓿� 欤检＜ 臧�旃橂ゼ 彀届稖頃橁赴 鞙勴暅 雼り皝頇旊悳 韽姼韽措Μ鞓るゼ 甑稌頃橂姅 瓴冹潉 氇╉憸搿� 頃橁碃 鞛堨姷雼堧嫟.
PMGC Holdings Inc. (NASDAQ: ELAB) a annonc茅 la vente de sa filiale de soins de la peau, Elevai Skincare, dans le cadre de sa transformation strat茅gique. La cession renforcera le bilan de l'entreprise gr芒ce 脿 environ 1,1 million de dollars en actions Carmell et une redevance de 5% sur les revenus des soins de la peau au cours des cinq prochaines ann茅es, ainsi que des paiements li茅s 脿 des 茅tapes.
La vente r茅duit les pertes op茅rationnelles et positionne PMGC pour de nouvelles opportunit茅s de croissance. L'entreprise poss猫de trois filiales : Elevai Biosciences, ax茅e sur les m茅dicaments esth茅tiques, y compris EL-22 pour la pr茅servation musculaire lors des traitements de perte de poids ; Elevai Research, tirant parti des subventions de recherche canadiennes ; et PMGC Capital, un v茅hicule d'investissement multi-strat茅gie.
L'entreprise vise 脿 poursuivre des acquisitions transformantes et 脿 b芒tir un portefeuille diversifi茅 ax茅 sur une croissance substantielle et la cr茅ation de valeur pour les actionnaires.
PMGC Holdings Inc. (NASDAQ: ELAB) hat den Verkauf ihrer Kosmetiksparte Elevai Skincare im Rahmen einer strategischen Neuausrichtung angek眉ndigt. Die Ver盲u脽ereung wird die Bilanz des Unternehmens durch etwa 1,1 Millionen US-Dollar in Carmell-Aktien und eine 5% Lizenzgeb眉hr auf die Kosmetikums盲tze in den n盲chsten f眉nf Jahren sowie Meilensteinzahlungen st盲rken.
Der Verkauf verringert die operativen Verluste und positioniert PMGC f眉r neue Wachstumschancen. Das Unternehmen hat drei Tochtergesellschaften: Elevai Biosciences, die sich auf 盲sthetische Medikamente konzentriert, einschlie脽lich EL-22 zur Muskelbewahrung w盲hrend der Gewichtsverlustbehandlungen; Elevai Research, die kanadische Forschungsstipendien nutzt; und PMGC Capital, ein Multi-Strategie-Investitionsvehikel.
Das Unternehmen strebt an, transformative 脺bernahmen zu verfolgen und ein diversifiziertes Portfolio mit nachhaltigem Wachstum und der Schaffung von Aktion盲rswerten aufzubauen.
- Sale of Elevai Skincare subsidiary reduces operational losses and cash burn
- Receives $1.1 million in Carmell stock as compensation
- Secured 5% royalty on skincare revenues for next five years plus milestone payments
- Strengthened balance sheet enables pursuit of larger acquisition opportunities
- Divestiture of revenue-generating subsidiary could impact short-term income
- Future performance depends on unidentified acquisition targets
- Success of transformation strategy remains uncertain
Insights
The strategic divestiture of Elevai Skincare represents a pivotal financial restructuring, yielding immediate and long-term benefits. The <money>$1.1 million</money> in Carmell stock provides immediate capital injection, while the <percent>5%</percent> royalty structure over five years creates a valuable revenue stream without operational overhead. The reduction in cash burn through elimination of a loss-generating subsidiary significantly improves PMGC's operational efficiency.
The transformation from a single-focus skincare company to a diversified holding company opens multiple revenue channels. The retention of Elevai Biosciences, with its EL-22 asset targeting the lucrative GLP-1/obesity market, positions PMGC in a high-growth sector. The establishment of PMGC Capital indicates a sophisticated approach to capital deployment and portfolio management.
The strategic pivot towards biopharmaceuticals through Elevai Biosciences, particularly the EL-22 program, targets a important unmet need in the expanding GLP-1 market. The focus on muscle preservation during weight loss treatment is particularly timely, as major players like Novo Nordisk and Eli Lilly dominate the GLP-1 space but haven't fully addressed this side effect. The Canadian research grants supporting Elevai Research provide cost-effective R&D opportunities and potential IP development.
The company's evolution from skincare to biotech represents a significant upside potential, especially given the massive market opportunity in obesity treatment, currently valued at over <money>$100 billion</money> globally. The probiotic approach to muscle preservation could create a valuable complementary therapy in the GLP-1 ecosystem.
This corporate restructuring demonstrates sophisticated portfolio management. The divestiture of the skincare business while maintaining upside through royalties and milestone payments shows astute deal structuring. The strategic shift from a single-product company to a diversified holding company with multiple subsidiaries creates multiple growth vectors and risk mitigation through diversification.
The creation of three distinct subsidiaries - Elevai Biosciences (drug development), Elevai Research (R&D) and PMGC Capital (investments) - establishes a robust framework for value creation. This structure enables efficient capital allocation and creates opportunities for both organic growth and strategic acquisitions. The focus on the GLP-1/obesity market through EL-22 shows strategic alignment with high-growth sectors.
Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions
Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency
NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the 鈥淐ompany鈥� or 鈥淧MGC鈥�) (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic divestiture marks a significant milestone in PMGC鈥檚 journey as a diversified holding company.
The sale was executed to maximize immediate financial benefit while securing future upside through structured royalties and milestone payments. It has notably strengthened PMGC鈥檚 balance sheet, reduced operational losses, and paved the way for new opportunities that align with the company's long-term vision.
Strategic Rationale: Think Bigger, Act Bold
The divestiture underscores PMGC's strategy to focus on acquiring transformative assets and businesses that deliver substantial growth and shareholder value. This sale frees the Company to look for bigger opportunities. Executive management鈥檚 goal is not incremental improvement but exponential growth through strategic acquisitions and steadfast execution.
Key Financial and Operational Highlights Post Sale
- Burn Rate Reduction: By eliminating a loss-generating subsidiary, PMGC ensures a leaner and more focused operational framework.
- Strengthened Financials: PMGC will receive approximately
$1.1 million in Carmell Corporation stock and retains a lucrative5% royalty on skincare revenues over the next five years, alongside milestone payment opportunities鈥�. - Growth Capital: Resources will now be channeled into high-potential assets, leveraging PMGC鈥檚 drive and expertise in creating shareholder value.
Why It Matters to Shareholders
This move demonstrates PMGC鈥檚 agility in adapting to market opportunities and its unwavering commitment to delivering shareholder value. The sale of Elevai Skincare is a step toward creating a portfolio of assets that reflects the company鈥檚 expansive vision and ambition.
For investors, this signals a moment of transition and opportunity. As PMGC positions itself to seize larger, more impactful opportunities, shareholders can look forward to the potential for increased returns, reduced risk, and sustainable growth.
Looking Ahead: Growth, Diversification, and Opportunity
PMGC is actively exploring accretive acquisitions and licensing opportunities in sectors poised for significant growth. The Company is focused on identifying undervalued assets and businesses that align with a vision of building a diversified and growth-oriented holding company.
PMGC Holdings Inc. will continue to expand its company portfolio with a focus on innovation, growth, and shareholder value creation. Current subsidiaries include:
Elevai Biosciences: a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity鈥檚 pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit .
Elevai Research: a research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian Universities to push the boundaries of innovation
PMGC Capital LLC: a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
The current subsidiaries and pending opportunities underscore PMGC鈥檚 focus on thinking bigger and its drive to build a growth-oriented portfolio.
About PMGC Holdings Inc.
PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Elevai Biosciences Inc., Elevai Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit .
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as 鈥渂elieves,鈥� 鈥渆xpects,鈥� 鈥減lans,鈥� 鈥減otential,鈥� 鈥渨ould鈥� and 鈥渇uture鈥� or similar expressions such as 鈥渓ook forward鈥� are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings鈥� filings with the United States Securities and Exchange Commission (鈥淪EC鈥�), including the 鈥淩isk Factors鈥� section of the Company鈥檚 Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC鈥檚 web site at聽. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
FAQ
What did PMGC Holdings (ELAB) receive from the sale of Elevai Skincare?
How will the Elevai Skincare sale affect PMGC Holdings' (ELAB) operations?
What are the current subsidiaries of PMGC Holdings (ELAB) after the skincare division sale?
What is PMGC Holdings' (ELAB) strategic focus following the Elevai Skincare sale?
